Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition
The treatment of patients with diabetes mellitus, which is characterized by defective insulin secretion and/or the inability of tissues to respond to insulin, has been studied for decades. Many studies have focused on the use of incretin-based hypoglycemic agents in treating type 2 diabetes mellitus...
Main Authors: | Yaochen Xie, Qian Zhou, Qiaojun He, Xiaoyi Wang, Jincheng Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-06-01
|
Series: | Acta Pharmaceutica Sinica B |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383522004580 |
Similar Items
-
Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
by: Geke Aline Boer, et al.
Published: (2020-12-01) -
Incretins-Based Therapies and Their Cardiovascular Effects: New Game-Changers for the Management of Patients with Diabetes and Cardiovascular Disease
by: Federico Bernardini, et al.
Published: (2023-07-01) -
Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity
by: Derek Ge, et al.
Published: (2022-12-01) -
Role of incretin based therapies in the treatment of diabetic kidney disease
by: Paola Fioretto, et al.
Published: (2018-11-01) -
Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption
by: Hideki Kitaura, et al.
Published: (2021-06-01)